Altasciences has been at the forefront of bioavailability (BA) and bioequivalence (BE) testing since our founding. Our team of pharmacokineticists leverages a study design database for more than 1,200 products or combinations, many based on in-house data.

Our clinics have specially designed units for dosing of up to 72 participants in a single group. We continually validate new bioanalytical methods and have developed over 620 validated methods to date.

Our experience includes:

• Absolute bioavailability testing as part of FIH studies, or later in clinical development.
• Comparative bioavailability studies on hundreds of new formulations or routes of administration; e.g., immediate vs. extended release and oral dosing vs. inhalation.
• Bioequivalence testing (small molecules and biologics) required for change in manufacturing, Hybrid or 505(b)(2) applications, or for generic and biosimilar submissions.